ArticleBMC ophthalmology2025
Different clinical presentations of persistent placoid maculopathy: a case series.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From white dot syndromes to primary inflammatory choriocapillaropathies (PICCPs): updating and expanding the spectrum through multimodal imaging.International journal of retina and vitreous · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPersistent placoid maculopathy is a rare clinical entity defined as idiopathic bilateral chorioretinopathy. We report four different clinical presentations of this pathology. CASE PRESENTATION: Case 1: A 63-year-old man presented with a persistent bilateral central scotoma. Persistent placoid maculopathy was diagnosed based on ophthalmological manifestations and multimodal imaging. A history of scalp tenderness and jaw claudication a week before visual symptoms was reported associated with increased C-reactive protein. A temporal artery biopsy confirmed the diagnosis of giant cell arteritis. Despite corticosteroid treatment, complete macular chorioretinal atrophy followed. Case 2: A 65-year-old woman was referred for bilateral blurred vision for one month. Visual acuity was 20/20 in both eyes and multimodal imaging confirmed the diagnosis of persistent placoid maculopathy. The patient was lost to follow-up due to the COVID-19 pandemic and presented one year later with decreased vision in the left eye of 20/200. Type 2 choroidal neovascularization was observed and treated with sub-tenon triamcinolone injection followed by intravitreal injection of Aflibercept allowing an improvement in visual acuity. Case 3: A 61-year-old man presented with sudden loss of vision in his right eye. A large submacular hemorrhage was observed on the right eye and hypopigmented white/yellowish plaque-like macular lesions on the other eye. Surgery with pneumatic displacement and intravitreal injection of Aflibercept was performed. No improvement in visual acuity was observed. Five months later, the contralateral eye was complicated by choroidal neovascularization and required intravitreal injections. Case 4: A 49-year-old man receiving immunosuppressive therapy after liver transplant was referred for bilateral decreased vision. The diagnosis of persistent placoid maculopathy was made, and corticosteroid treatment was initiated. After three months, chorioretinal lesions decreased and vision recovered.
conclusionsWe report the first case series of clinical presentations of persistent placoid maculopathy, which expand upon the reported ocular manifestations of this condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.